Compare FFIN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIN | MIRM |
|---|---|---|
| Founded | 1890 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.2B |
| IPO Year | 1994 | 2019 |
| Metric | FFIN | MIRM |
|---|---|---|
| Price | $33.31 | $104.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $37.50 | ★ $104.92 |
| AVG Volume (30 Days) | ★ 711.4K | 594.6K |
| Earning Date | 04-24-2026 | 04-03-2026 |
| Dividend Yield | ★ 2.28% | N/A |
| EPS Growth | 12.23 | ★ 53.75 |
| EPS | ★ 1.26 | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $16.90 | $55.91 |
| Revenue Next Year | $6.41 | $23.97 |
| P/E Ratio | $26.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.44 | $36.88 |
| 52 Week High | $38.74 | $107.41 |
| Indicator | FFIN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 68.04 |
| Support Level | $33.04 | $98.70 |
| Resistance Level | $34.04 | $107.41 |
| Average True Range (ATR) | 1.02 | 3.35 |
| MACD | -0.13 | -0.46 |
| Stochastic Oscillator | 41.39 | 75.10 |
First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto. It derives maximum revenue from Construction and Development Segment.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.